COVID-19 drug trial halted: did INB03 help High-Risk patients?

NCT ID NCT04370236

Terminated Disease control Sponsor: Inmune Bio, Inc. Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 20, 2026

Summary

This study tested a drug called INB03 (XPro1595) to see if it could stop COVID-19 patients from developing serious lung complications. The trial included 79 high-risk adults (e.g., over 65, obese, or with conditions like diabetes or heart disease). The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Baptist Clinical Research Institute

Memphis, Tennessee, 38120, United States
Baptist Memorial Hospital-DeSoto

Southard, Missouri, 38671, United States
Jewish Hospital

Louisville, Kentucky, 40202, United States
Memorial Hermann

Houston, Texas, 77030, United States
Memorial Hermann Southeast

Houston, Texas, 77089, United States
Mississippi Baptist

Kosciusko, Mississippi, 39090, United States
NEA Baptist

Jonesboro, Arkansas, 72401, United States
Richmond University Medical Center

Staten Island, New York, 10312, United States
St. Bernard's

Jonesboro, Arkansas, 72401, United States

Conditions

Explore the condition pages connected to this study.

COVID-19